A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
ZX-101A-201 is a phase I, open-label, multicenter study which includes dose escalation and
dose expansion of ZX-101A. It is designed to evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamic (PD), and antitumor activity of ZX-101A in patients
with advanced solid tumors.